REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/20/2026
Back to search
Official data from USPTO
LIMINAL BIOSCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Quick snapshot
ST13
US500000079293279Class
5, 40, 42, 44, 45
Filing
79293279
Registration
6422386
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
07/20/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 40, 42, 44, 45
Filing date
04/17/2020
Registration date
07/20/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/20/2021
Last transaction
07/20/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
CA
Examiner
THOMAS, JULIE
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of two interlocking incomplete triangles in gradients of teal and light green to the left of a vertical gray line and the wording "LIMINAL BIOSCIENCES" in gray. The color white represents background and is not a feature of the mark.
Holders and representatives
Holders
Liminal BioSciences Inc.
Representatives
Timothy H. Hiebert Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 5Class 40Class 42Class 44Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of brain diseases and disorders, namely, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; anti-viral agents; antibiotics; antivirals; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hypercholesterolemia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident, stroke, Parkinson's disease, multiple sclerosis, myasthenia gravis
Class 40
Manufacture of pharmaceuticals to the order and specification of others
Class 42
Development of pharmaceutical preparations and medicines; pharmaceutical product evaluation; pharmaceutical research and development; pharmaceutical research services; research on the subject of pharmaceuticals
Class 44
Pharmaceutical advice; pharmaceutical consultancy services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing information to patients in the field of administering medications; medical care services relating to patient treatment, excluding services in the field of psychology and mental health
Class 45
Providing personal support services for families of patients with life threatening disorders, namely, emotional counseling and emotional support, and coordinating the procurement and administration of medication; providing companionship services for families of patients with life threatening disorders
Publications
History of USPTO decisions and trademark events.
30 publications found
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
12/27/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/26/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/26/2021
FIMP
FINAL DISPOSITION PROCESSED
11/26/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/20/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/20/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/04/2021
PUBO
PUBLISHED FOR OPPOSITION
05/04/2021
GPNX
NOTIFICATION PROCESSED BY IB
05/02/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/14/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/14/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/14/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/29/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
03/29/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/29/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
03/29/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/29/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/22/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/21/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/21/2021
RFNT
REFUSAL PROCESSED BY IB
10/19/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/01/2020
RFRR
REFUSAL PROCESSED BY MPU
09/30/2020
MAFR
APPLICATION FILING RECEIPT MAILED
09/15/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/13/2020
CNRT
NON-FINAL ACTION WRITTEN
09/12/2020
DOCK
ASSIGNED TO EXAMINER
09/11/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/11/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/10/2020
Continuous trademark protection
Get notified about every new filing that threatens LIMINAL BIOSCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.